Interviews on biotechnology

kai pinkernell glycostem nk cell therapy

Interview 27 Sep 2022

Natural killer cells: a thriving frontier in allogeneic cell therapy

Kai Pinkernell, chief medical officer at Glycostem, discusses how natural killer (NK) cell therapies could usher in off-the-shelf cancer immunotherapies. Since their first approvals in 2017, chimeric antigen receptor (CAR)-T cell immunotherapies have showcased the potential of immuno-oncology in providing long-lasting treatments for cancer. This impact was felt in not just the CAR-T cell therapy […]

September 27, 2022 - 6 minutesmins - By Jonathan Smith

Interview 27 Sep 2022

Europe’s first lab-grown fish company Bluu Seafood is aiming for sustainability

Overfishing is a global issue that negatively impacts the ecosystem and our access to fish protein. One solution to overfishing is producing fish products in the lab from harvested animal cells. This can help feed the world while using up fewer resources and without endangering wild fish populations. As the world’s population continues to grow, […]

September 27, 2022 - 5 minutesmins - By Omnia Ibrahim

Interview 26 Sep 2022

Rapid diagnostics are needed to tackle antimicrobial resistance

As the antimicrobial resistance (AMR) crisis grows, bacterial infections are becoming harder to treat. Chris Lock, vice president of R&D at the mass spectrometry specialist SCIEX, discusses how rapid diagnostics can help doctors wield antimicrobial treatments more effectively. The AMR crisis is growing increasingly severe, resulting in superbugs that are able to shrug off multiple […]

September 26, 2022 - 5 minutesmins - By Jonathan Smith

Interview 12 Sep 2022

Orchestrating the evolving cell therapy supply chain

In a few decades, the cell and gene therapy sector has diversified into many complex technologies. Paul Viggers, chief commercial officer at the U.K. firm TrakCel, explains how the company’s platform can tackle the intricacies of developing cell and gene therapies. After cell and gene therapy funding smashed records in 2021, the emerging sector has […]

September 12, 2022 - 5 minutesmins - By Jonathan Smith

Interview 31 Aug 2022

How CDMOs keep pace with trends in advanced therapies

Advanced therapies including cell and gene therapies are exploding in demand, but the manufacturing process can be difficult. Jean-Christophe Hyvert, president of biologics and cell & gene at the CDMO Lonza, sheds light on the latest trends in advanced therapies and how manufacturers are keeping up. In 2021, global funding going to cell and gene […]

August 31, 2022 - 8 minutesmins - By Jonathan Smith

Interview 29 Aug 2022

Making a success out of technology transfer at UCLB

Having a good relationship with the technology transfer office at your university can be key to creating a successful startup. Anne Lane, CEO of University College London’s (UCL’s) commercialization company UCLB, discusses recent successes and shares insights on how to advance new innovations. Anne Lane began her career as a scientist, completing a PhD at […]

August 29, 2022 - 13 minutesmins - By Helen Albert

Interview 22 Aug 2022

Hiring practices are shifting as biotech goes digital

Cloud computing is becoming increasingly prevalent as demand for global collaborations grows. Sajith Wickramasekara, founder and CEO of the cloud lab software provider Benchling, explains how this shift is affecting the labor market in the biotech industry. The biotech industry is becoming increasingly enmeshed with the world of digital technology, as companies search for ways […]

August 22, 2022 - 5 minutesmins - By Jonathan Smith

Interview 19 Aug 2022

How re-engineering antibodies can prevent allergies

The California startup IgGenix is aiming to re-engineer antibodies that mediate allergic responses into antibodies that can block this response. We spoke with IgGenix’s CEO Jessica Grossman and CTO Derek Croote to understand the potential of such a therapy. Allergies are overreactions of the immune system to foreign substances that are normally harmless. Worldwide, and […]

August 19, 2022 - 9 minutesmins - By Omnia Ibrahim

Interview 19 Aug 2022

Delaying menopause could slow the aging process

After decades of neglect, women’s health is attracting increasing interest in the biotech industry. The U.S. startup Oviva Therapeutics aims to develop hormonal therapies that can delay menopause as part of the aging process. Many biotech companies fighting aging are attracting massive cash infusions. One well-known example is Altos Labs, which launched in Silicon Valley […]

August 19, 2022 - 6 minutesmins - By Jonathan Smith

Radiopharmaceuticals for cancer therapy: interview with Steffen Schuster

Interview 17 Aug 2022

The challenges of developing radiopharmaceuticals for cancer

Radiopharmaceuticals have been a relatively niche area of cancer therapy for decades. Steffen Schuster, the CEO of Germany’s ITM Group, outlines how the space is heating up, and how much nuclear medicine centers still need to grow. There are many areas in oncology research that are generating investor excitement, including immuno-oncology, DNA damage repair and […]

August 17, 2022 - 5 minutesmins - By Jonathan Smith

Interview 10 Aug 2022

How the UK precision breeding bill could unshackle gene editing

The U.K. is considering lowering restrictions on gene-edited crops. PacBio’s Neil Ward explains how the changes could impact the gene editing landscape. CRISPR gene editing technology has changed the game in the biotech industry by making it easier than ever before to make small changes to the genome. In addition to myriad healthcare applications, the […]

August 10, 2022 - 6 minutesmins - By Jonathan Smith

Interview 21 Jul 2022

Finding investment opportunities in a bleak biotech stock market

The situation remains difficult in public markets as biotech stocks struggle to recover from a 50% decline over the past year. However, the venture capital (VC) firm Sofinnova Partners is no stranger to downturns, and partner Joe Anderson explains how the industry is shifting in favor of life sciences investors. It’s a tough time to […]

July 21, 2022 - 7 minutesmins - By Jonathan Smith

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us